Business Context and Reporting Period
This Form 8-K reports on the results of the 2025 Annual Meeting of Stockholders for enVVeno Medical Corporation, held on December 11, 2025. The record date for the meeting was October 17, 2025. As of the record date, there were 20,216,176 shares of common stock outstanding and entitled to vote. A total of 11,058,255 shares were represented at the meeting, constituting 54.70% of the voting power.
Key Financial Metrics
This filing is a Current Report regarding corporate governance and shareholder voting outcomes. It does not provide financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes and Voting Results
The following material outcomes were determined by shareholder vote:
- Director Elections: Stockholders elected Matthew M. Jenusaitis and Robert A. Berman as Class II directors for three-year terms expiring in 2028.
- Executive Compensation: Stockholders approved the advisory vote on executive compensation, though a significant portion of votes were withheld or against.
- Auditor Ratification: Stockholders ratified the appointment of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Equity Incentive Plan Rejection: Stockholders voted against the adoption of the 2025 Equity Incentive Plan. Consequently, the 2016 Omnibus Incentive Plan remains in full force and effect.
- Reverse Stock Split Authorization: Stockholders granted the Board authority to effectuate a reverse stock split at a ratio between one-for-five and one-for-thirty-five, at the Board's sole discretion.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future financial guidance, operational outlook, or specific risk factors beyond the implications of the voting results. The rejection of the 2025 Equity Incentive Plan may impact the company's ability to grant new equity awards under that specific plan, necessitating reliance on the existing 2016 plan. The authorization of a reverse stock split suggests potential liquidity or listing standard concerns, though the timing and specific ratio remain at the Board's discretion.
Investor Verification Checklist
- Verify the remaining share availability and terms under the existing 2016 Omnibus Incentive Plan following the rejection of the 2025 plan.
- Monitor Board announcements regarding the timing and specific ratio of the authorized reverse stock split.
- Review the voting breakdown for the executive compensation proposal, noting the high number of votes against or withheld relative to votes for.
- Confirm the company's compliance with NASDAQ listing standards given the authorization of a reverse stock split.